Deciphera reports updated Phase I data for DCC-2618 in GIST

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) reported updated data at the American Society of Clinical Oncology (ASCO) meeting in Chicago from heavily pretreated patients with gastrointestinal stromal tumors (GIST) who received the company's DCC-2618 in a Phase I trial.

This year, Deciphera plans to start the Phase III INTRIGUE trial of DCC-2618 as second-line treatment of GIST. The product is also in the Phase III INVICTUS trial in heavily pretreated fourth-line or greater GIST patients...